Billing Instructions for Beneficiaries Enrolled in MA Plans for Services Covered by Decision Memo CAG-00451N

MLN Matters Number: SE19024
Article Release Date: October 24, 2019
Effective Date: August 7, 2019
Implementation Date: August 7, 2019

This article conveys information on the National Coverage Determination (NCD) requiring coverage of Chimeric Antigen Receptor (CAR) T-cell therapy for cancer. For more information on the National Coverage Determination, see the decision memorandum at

The Centers for Medicare & Medicaid Services (CMS) is providing this information for hospitals providing CAR T-cell therapy to beneficiaries enrolled in Medicare Advantage (MA) plans. Make sure your billing staff is aware of these instructions.

View the complete CMS Medicare Learning Network (MLN) Matters (MM) Special Edition (SE)19024.

            Last Updated Mon, 28 Oct 2019 08:56:14 +0000